Welcome to our dedicated page for Icad news (Ticker: ICAD), a resource for investors and traders seeking the latest updates and insights on Icad stock.
iCAD Inc (NASDAQ: ICAD) delivers AI-powered medical imaging solutions that transform cancer detection through advanced analytics. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s innovations in early diagnosis technology.
Access official announcements covering regulatory milestones, clinical study results, and strategic partnerships. Stay informed about developments in mammography AI systems, radiation therapy advancements, and global market expansions. Our curated repository ensures timely access to earnings reports, product launch details, and industry recognition updates.
Key content categories include FDA clearances for new AI algorithms, collaborations with radiology networks, and enhancements to the ProFound Breast Health Suite. Bookmark this page for direct access to primary sources about iCAD’s contributions to precision medicine and workflow optimization technologies.
iCAD, a leader in cancer detection technology, reported its Q1 2022 results, revealing a 13.0% decline in total revenue to $7.5 million, attributed to decreases in both product and service revenues. The company recorded a GAAP net loss of $3.5 million, compared to a loss of $1.6 million in Q1 2021. Despite a 70.6% gross profit margin, operating expenses rose by 12.9%. Notably, iCAD secured an enterprise agreement for ProFound AI and is advancing clinical research, with promising developments in its GLIOX trial.
iCAD recently highlighted its ProFound AI technology as the leading solution in a competitive trial conducted by Wake Radiology, which operates 14 imaging centers in North Carolina. The upcoming webinar, part of iCAD's series 'ProFound Insights, ProFound Impact,' will discuss the advantages of ProFound AI and its flexibility in reading mammograms across various systems. The event will feature experts from Wake Radiology and aims to showcase the effectiveness of iCAD's solutions in enhancing breast imaging practices.
iCAD, Inc. (NASDAQ: ICAD), a leader in cancer detection and therapy solutions, announced it will release its financial results for Q1 2022 on May 11, 2022, after market close. The company will also host a conference call at 4:30 PM ET the same day, where details on financial performance will be discussed. Interested parties can join via the provided domestic and international numbers or through a webcast. The upcoming financial results are anticipated to provide insights into the company’s growth and strategic direction.
iCAD reports strong commercial momentum for its ProFound AI breast health solutions, outperforming competitors in clinical performance and workflow efficiency. Key clients, including Wake Radiology and Kettering Health, have transitioned to ProFound AI, citing significant improvements in accuracy and efficiency for mammography readings. The AI integration has been praised for reducing false positives and enhancing patient care. Ongoing improvements to the technology have further solidified customer satisfaction and market positioning.
iCAD (NASDAQ: ICAD) anticipates a preliminary revenue of $7.5 million for Q1 2022, reflecting ongoing growth in the medical technology sector focused on cancer detection and therapy solutions. The company has appointed Timothy Norris Irish as the new Chairman of the Board, succeeding Michael Klein. Irish brings extensive experience from the healthcare sector. Furthermore, CFO Charles Carter will be leaving the position, with an interim CFO to be announced soon. iCAD remains optimistic about its commercial infrastructure and future prospects.
iCAD announced the launch of a new webinar series called ProFound Insights, ProFound Impact, starting with an event titled “Why Kettering Health Traded out Previous AI Software for ProFound AI®”. The first session is scheduled for April 27, 2022, featuring experts from Kettering Health, an enterprise breast care provider in southwest Ohio. The event will showcase customer success stories, emphasizing the effectiveness of ProFound AI in enhancing reading efficiency and patient care, as noted by Kettering's Director and Medical Director.
iCAD announced positive developments regarding its Xoft electronic brachytherapy (eBx) technology, particularly in the international multi-center GLIOX trial.
Clinicians across Spain report successful treatments using the Xoft System for recurrent glioblastoma and various cancers, showcasing its versatility.
The system, FDA-cleared and CE marked, offers efficient treatment with minimal side effects, potentially replacing weeks of traditional therapy. Preliminary data indicates promising outcomes, with extended survival rates for patients treated with Xoft compared to the control group.
iCAD, Inc. (NASDAQ: ICAD) showcased its innovative Breast AI solutions at the HIMSS Global Health Conference in Orlando, FL, from March 14-18, 2022. The company highlights the capabilities of ProFound AI® for Digital Breast Tomosynthesis, which enhances reading accuracy and reduces reading time significantly. iCAD's suite includes tools for cancer detection, breast density assessment, and risk evaluation, all designed to improve workflow and interoperability in healthcare systems. The technology integrates with NVIDIA AI Enterprise, optimizing IT environments to enhance cancer detection capabilities.
iCAD will showcase its award-winning breast health solutions at the inaugural Pink Paradigm Summit and the NCoBC Annual Conference in Las Vegas from March 11-16, 2022. With innovations like ProFound AI for Digital Breast Tomosynthesis and the PowerLook® Breast Density Assessment, iCAD's technology aims to enhance breast cancer detection and patient care. Presentation by Mark Traill, MD, will highlight the benefits of AI in breast cancer risk assessment. CEO Stacey Stevens emphasized the significance of these gatherings to connect with clinical leaders and advocates.
iCAD, a leader in innovative cancer detection technology, is set to participate in the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. Stacey Stevens, President and CEO, will present on March 17, 2022, at 8:00 a.m. EST. Interested parties can view the webcast at the provided link. iCAD is renowned for its advanced cancer detection and therapy solutions, aimed at improving patient outcomes. The company addresses various risks and uncertainties in its forward-looking statements, emphasizing a commitment to innovation in the healthcare sector.
FAQ
What is the current stock price of Icad (ICAD)?
What is the market cap of Icad (ICAD)?
